世界の機能性腸障害治療薬市場 – 業界動向と2029年までの予測

市場分析と規模

近年、機能性腸障害治療薬市場は予測期間中に急速に成長すると予想されています。国連の世界人口高齢化ハイライト2020調査によると、世界の高齢者人口は2020年の7億2,700万人から2050年までに15億人に増加し、ほぼ2倍になると予測されています。一方、2020年の高齢者人口の割合は約9.3％で、2050年までに16％に増加すると予想されています。高齢者は機能性腸障害のリスクが高いため、ヘルスケア分野では機能性腸障害治療薬の需要が高まっています。

Data Bridge Market Research の分析によると、機能性腸障害治療薬市場は 2021 年に 20 億 7,100 万米ドルと評価され、2022 年から 2029 年の予測期間中に 5.80% の CAGR を記録し、2029 年までに 32 億 5,000 万米ドルに達すると予想されています。Data Bridge Market Research チームがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みが含まれています。

市場の定義

過敏性腸症候群、慢性の膨満感、下痢、便秘はすべて、症状を緩和するためにさまざまな方法で作用する機能性腸障害薬で治療されます。従来の検査で病理学的所見が認められない慢性の胃腸(GI) 症状 (胃痛、嚥下障害、消化不良、下痢、便秘、膨満感など) が機能性胃腸障害 (FGID) の特徴です。

レポートの範囲と市場セグメンテーション

機能性腸障害治療薬?市場の動向

ドライバー

• 機能性胃腸障害（FGID）の発生率の増加

機能性胃腸障害 (FGID) の発生率の上昇は、機能性腸障害薬市場の成長に影響を与えると予想されます。喫煙習慣の増加と人々の座りがちな生活習慣は、FGID の原因の一部です。

• 医療インフラへの投資増加

機能性腸障害治療薬市場の成長率に影響を与えるもう一つの重要な要因は、医療費の増加であり、これがインフラの改善に役立っています。

さらに、公的機関や民間組織による認知度向上に向けた取り組みの増加により、機能性腸障害薬市場は拡大するでしょう。また、可処分所得の増加やストレスやうつ病の増加により、機能性腸障害薬市場は拡大するでしょう。これに伴い、高齢者人口の増加や有利な償還方針により、市場の成長率が高まります。

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the functional bowel disorder agents? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the functional bowel disorder agents? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the functional bowel disorder agents? market. Additionally, side effects of functional bowel disorder agents? and lack of awareness will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This functional bowel disorder agents? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the functional bowel disorder agents? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

functional gastrointestinal disorders (FGIDs) are quite frequent, with a global incidence of 40%. They are more common in women than in males, and their prevalence diminishes with age. They are responsible for 12% of primary care burden and 30% of gastrointestinal outpatient consultations. More over two-thirds of FGID patients will have seen a doctor in the previous year, and 40% will take regular medication. This increases the use of functional bowel disorder agents.

Functional bowel disorder agents? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Functional Bowel Disorder Agents? Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The functional bowel disorder agents market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the functional bowel disorder agents market's revenue trajectory.

Global Functional Bowel Disorder Agents? Market Scope

The functional bowel disorder agents? market is segmented on the basis of drug class, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Anticholinergics
• Chloride Channel Activators
• Guanylate Cyclase-C Agonists
• NHE3 Inhibitors
• Peripheral Opioid Receptor Antagonists
• Peripheral Opioid Receptor Mixed Agonists/Antagonists
• Serotoninergic Neuroenteric Modulators

On the basis of drug class, the global hepatic drugs market is segmented into anticholinergics, chloride channel activators, guanylate cyclase-C agonists, NHE3 inhibitors, peripheral opioid receptor antagonists, peripheral opioid receptor mixed agonists/antagonists, and serotoninergic neuroenteric modulators.

Application

• Irritable Bowel Syndrome
• Chronic Bloating
• Diarrhea
• Constipation
• Others

On the basis of application, the global hepatic drugs market is segmented into irritable bowel syndrome, chronic bloating, diarrhea, constipation and others.

Dosage

• Injection
• Tablet
• Others

On the basis of dosage, the functional bowel disorder agents? market is segmented into injection, tablet and others.  

Route of Administration

• Intravenous
• Oral
• Others

The route of administration segment for the functional bowel disorder agents? market is segmented into intravenous, oral and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the functional bowel disorder agents? market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the functional bowel disorder agents? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Functional Bowel Disorder Agents Market Regional Analysis/Insights

The Functional bowel disorder agents? market is analysed and market size insights and trends are provided by country, drug class, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Functional bowel disorder agents? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the functional bowel disorder agents? market because of the well-established healthcare sector in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Functional Bowel Disorder Agents? Market Share Analysis

The Functional bowel disorder agents? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to functional bowel disorder agents? market.

Some of the major players operating in the functional bowel disorder agents? market are:

• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.( Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Takeda Pharmaceutical Company Limited (Japan)
• Pfizer Inc. (US)
• グラクソ・スミスクライン（英国）
• アストラゼネカ（英国）
• ジョンソン・エンド・ジョンソン プライベート・リミテッド（米国）
• ベーリンガーインゲルハイムインターナショナルGmbH（ドイツ）
• アステラス製薬株式会社（日本）
• アラガン（アイルランド）
• 田辺三菱製薬株式会社（日本）
• 協和キリン株式会社（日本）
• リミナルバイオサイエンス社（カナダ）
• Avexgen Therapeutics, Inc.（米国）
• アッヴィ社（米国）    

SKU-68166